Answers are grounded in this paper and cite their sources.
Schizophrenia is a heterogeneous neuropsychiatric illness with disrupted dopaminergic, serotonergic and glutamatergic neurotransmission, neuroinflammation and synaptic dysfunction for which, single-target antipsychotics have limited effectiveness. Nardostachys jatamansi, Withania somnifera, Bacopa monnieri and Rauvolfia serpentina are well-described in Ayurveda for psychosis, cognitive decline and mood disturbance, symptoms directly overlapping with the Schizophrenia spectrum. However, the mechanistic basis of their combinatorial effect across Schizophrenia-associated molecular targets remains undiscovered. The study systematically identified the multi-target, multi-component pharmacological mechanisms of a four-herb combination against Schizophrenia with an integrated network pharmacology and computational perspective and elucidated the relevant mechanistic basis for their rational application as polyherbal strategy. Using ADMET criteria, bioactive compounds of four medicinal plants were screened, and herb-disease targets were mapped using Venn diagram analysis. PPI network construction revealed 21 hub genes which were verified with SZDB 2.0. GO and pathway enrichment analyses; molecular docking of nine top priority targets; toxicity profiling; scaffold comparison with FDA-approved antipsychotics. The herb-target network showed extensive coverage of dopaminergic, serotonergic and glutamatergic pathways with 21 hub genes identified, nine of which were prioritized for docking. GO and pathway enrichment showed that neurotransmitter modulation was a prominent process. Docking confirmed potential favorable binding interactions, and scaffold analysis displayed that these compounds obtained structural similarities to FDA-approved antipsychotics. This study offers computational systems-level, mechanism-based evidence for the potential combinatorial effects of four-herb combination toward multiple schizophrenia-associated pathways. These results provide a rationale for the experimental validation and optimization of multi-component herbal interventions in schizophrenia.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: